Abstract
Purpose. Amphotericin B (AmB) in small, unilamellar liposomes (AmBisome ®) has an improved therapeutic index, and altered pharmacokinetics. The repeat-dose safety and toxicokinetic profiles of AmBisome were studied at clinically relevant doses.
Methods. Beagle dogs (5/sex/group) received intravenous AmBisome (0.25, 1,4, 8, and 16 mg/kg/day), empty liposomes or vehicle for 30 days. AmB was determined in plasma on days 1, 14, and 30, and in tissues on day 31. Safety parameters included body weight, clinical chemistry, hematology and microscopic pathology.
Results. Seventeen of twenty animals receiving 8 and 16 mg/kg were sacrificed early due to weight loss caused by reduced food intake. Dose-dependent renal tubular nephrosis, and other effects characteristic of conventional AmB occurred at 1 mg/kg/day or higher. Although empty liposomes and AmBisome increased plasma cholesterol, no toxicities unique to AmBisome were revealed. Plasma ultrafiltrates contained no AmB. AmBisome achieved plasma levels 100-fold higher than other AmB formulations. AmBisome kinetics were non-linear, with clearance and distribution volumes decreasing with increasing dose. This, and nonlinear tissue uptake, suggest AmBisome disposition was saturable.
Conclusions. AmBisome has the same toxic effects as conventional AmB, but they appear at much higher plasma exposures. AmBisome's non-linear pharmacokinetics are not associated with increased risk, as toxicity increases linearly with dosage. Dogs tolerated AmBisome with minimal to moderate changes in renal function at doses (4 mg/kg/day) producing peak plasma concentrations of 18−94 µg/mL.
Similar content being viewed by others
REFERENCES
J. E. Bennett. Antimicrobial Agents: Antifungal Agents. In J. G. Hardman and L. E. Limbird (eds.), Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th ed., McGraw-Hill, New York, 1996, Ch. 49.
D. B. Bhathena, W. E. Bullock, C. E. Nuttall, and R. G. Luke. The effects of amphotericin B therapy on the intrarenal vasculature and renal tubules in man. Clin. Nephrol. 9:103–110 (1978).
I. Bekersky, R. M. Fielding, D. Buell, and I. Lawrence. Lipid-based amphotericin B formulations: from animals to man. Pharmaceut. Sci. Technol. Today 2:230–236 (1999).
R. M. Fielding, A. W. Singer, L. H. Wang, S. Babbar, and L. S. S. Guo. Relationship of pharmacokinetics and tissue distribution to reduced toxicity of colloidal amphotericin B in dogs. Antimicrob. Agents Chemother. 36:299–307 (1992)
G. Lopez-Berestein, R. Mehta, R. L. Hopfer, et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome encapsulated amphotericin B. J. Infect. Dis. 147:939–945 (1983).
J. Graybill, P. Craven, R. Taylor, D. Williams, and W. Magee. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J. Infect. Dis. 145:748–752 (1982).
C. Tremblay, M. Barza, C. Fiore, and F. Szoka. Efficacy of liposome intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 26:170–17 (1984).
K. M. Wasan, A. L. Kennedy, S. M. Cassidy, et al. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146–3152 (1998).
J. P. Sculier, A. Coune, F. Meunier, et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur. J. Cancer Clin. Oncol. 24:527–538 (1988).
G. Lopez-Berestein, V. Fainstein, R. Hopfer, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study. J. Infect. Dis. 151:704–710 (1985).
R. P. Rapp, P. O. Gubbins, and M. E. Evans. Amphotericin B lipid complex. Ann. Pharmacother. 31:1174–86 (1997).
R. T. Proffitt, A. Satorius, S.-M. Chiang, et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B): 49–61 (1991).
J. P. Adler-Moore, S.-M. Chiang, A. Satorius, et al. Treatment of murine candidosis and ctyptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28(Suppl. B):63–71 (1991).
K. V. Clemons and D. A. Stevens. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32:465–472 (1993).
T. J. Walsh, V. Yeldandi, M. McEvoy, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:2391–2398 (1998).
T. J. Walsh, R. W. Finberg, C. Arndt, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl. J. Med. 340:764 (1999).
A. J. Coukell and R. N. Brogden. Liposomal amphotericin B: Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55:585–612 (1998).
R. Janknegt, S. deMarie, I. A. J. M. Bakker-Woudenberg, et al. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin. Pharmacokinet. 23:279–291 (1992).
A. Alak, S. Moys, and I. Bekersky. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Ther. Drug Monit. 18:604–609 (1996).
R. M. Fielding, G. Mukwaya, and R. A. Sandhaus. Clinical and preclinical studies with low-clearance liposomal Amikacin (MiKasome®). In M. C. Woodle and G. Storm (eds.), Long-Circulating Liposomes: Old Drugs, New Therapeutics, Springer-Verlag, New York, 1998, Ch. 15.
P. D. Hoeprich, A. C. Huston, and B. M. Wolfe. Toxicity of Amphotericins on Chronic Administration to Mongrel Dogs. Diagn. Microbiol. Infect. Dis. 3:47–58 (1985).
J. P. Adler-Moore and R. T. Proffitt. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3:429–450 (1993).
G. W. Boswell, I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:263–268 (1998).
H. Harashima and H. Kiwada. Liposomal targeting and drug delivery: kinetic consideration. Adv. Drug Del. Rev. 19:425–444 (1996).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bekersky, I., Boswell, G.W., Hiles, R. et al. Safety and Toxicokinetics of Intravenous Liposomal Amphotericin B (AmBisome ®) in Beagle Dogs. Pharm Res 16, 1694–1701 (1999). https://doi.org/10.1023/A:1018997730462
Issue Date:
DOI: https://doi.org/10.1023/A:1018997730462